Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial.
Coates TJ, Kulich M, Celentano DD, Zelaya CE, Chariyalertsak S, Chingono A, Gray G, Mbwambo JK, Morin SF, Richter L, Sweat M, van Rooyen H, McGrath N, Fiamma A, Laeyendecker O, Piwowar-Manning E, Szekeres G, Donnell D, Eshleman SH; NIMH Project Accept (HPTN 043) study team.
Lancet Glob Health, 2014: 2(5): e267-277, 10.1016/S2214-109X(14)70032-4
A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.
Cousins MM, Konikoff J, Sabin D, Khaki L, Longosz AF, Laeyendecker O, Celum C, Buchbinder SP, Seage GR, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Kobin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.
PLoS One, 2014: 9(6): e101043, 10.1371/journal.pone.0101043
Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.
Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O.
J Acquir Immune Defic Syndr, 2014: 65(4): 390-396, 10.1097/QAI.0000000000000006
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay.
Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS, 2014: 28(8): 1227-32, 10.1097/QAD.0000000000000221.
Inter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infection.
Curtis KA, Longosz AF, Kennedy MS, Keating S, Heitman J, Laeyendecker O, Owen SM.
PLoS One, 2013: 8(10): 77765, 10.1371/journal.pone.0077765
Cross-sectional HIV incidence estimation in HIV prevention research.
Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH.
J Acquir Immune Defic Syndr, 2013: 63 Supplement 2: S233-9, 10.1097/QAI.0b013e3182986fdf
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043).
Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk D, Mullis CE, Chin C, Swanson P, Hackett J Jr, Clarke W, Marzinke M, Szekeres G, Gray G, Richter L, Alexandre MW, Chariyalertsak S, Chingono A, Celentano DD, Morin SF, Sweat M, Coates T, Eshleman SH.
PLoS One, 2013: 8(7): e68349, 10.1371/journal.pone.0068349
Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.
Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, Brookmeyer R, Nalugoda F, Kigozi G, Kagaayi J, Tobian AA, Wawer M, Gray RH, Quinn TC, Laeyendecker O.
AIDS Res Hum Retroviruses, 2013: 29(8): 1146-50, 10.1089/AID.2012.0105

Pages

  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Contact

Tel: 410-955-3551

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Justin Lessler
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6545
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2021 Infectious Disease Dynamics
Website by Manta Ray Media